drugset / Trial / NCT04828564
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Phase 2/3
Unknown
100 enrolled
The Scientific and Technological Research Council of Turkey
Ankara City Hospital Bilkent · collabKoç University · collabMonitorCRO · collabUmraniye Education and Research Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a national, multicenter, open-label, randomized, phase II/III trial that evaluates the efficacy and safety of favipiravir and ribavirin in the treatment of patients with confirmed COVID-19 observed within 72 hours. Approximately 100 patients will be randomized in 1:1 ratio and divided into two groups.
Timeline
- Start
- 2021-04
- Primary completion
- 2021-09-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Favipiravir | Small molecule | 600 mg | Oral |
| Subject | Ribavirin | Small molecule | 400 mg | Oral |